Literature DB >> 2299358

(R)-N-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid binds with high affinity to the brain gamma-aminobutyric acid uptake carrier.

C Braestrup1, E B Nielsen, U Sonnewald, L J Knutsen, K E Andersen, J A Jansen, K Frederiksen, P H Andersen, A Mortensen, P D Suzdak.   

Abstract

(R)-N-[4,4-Bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid (NO 328) has previously been shown to be a potent anticonvulsant in both mice and rats. Here, we report that NO 328 is a potent inhibitor of gamma-[3H]aminobutyric acid [( 3H]GABA) uptake in a rat forebrain synaptosomal preparation (IC50 = 67 nM) and in primary cultures of neurons and astrocytes. Inhibition of [3H]GABA uptake by NO 328 is apparently of a mixed type when NO 328 is preincubated before [3H]GABA uptake; the inhibition is apparently competitive without preincubation. NO 328 itself is not a substrate for the GABA uptake carrier, but NO 328 is a selective inhibitor of [3H]GABA uptake. Binding to benzodiazepine receptors, histamine H1 receptors, and 5-hydroxytryptamine1A receptors was inhibited by NO 328 at 5-30 microM, whereas several other receptors and uptake sites were unaffected. [3H]NO 328 showed saturable and reversible binding to rat brain membranes in the presence of NaCl. The specific binding of [3H]NO 328 was inhibited by known inhibitors of [3H]GABA uptake; GABA and the cyclic amino acid GABA uptake inhibitors were, however, less potent than expected. This indicates that the binding site is not identical to, but rather overlapping with, the GABA recognition site of the uptake carrier. The affinity constant for binding of [3H]NO 328 is 18 nM, and the Bmax is 669 pmol/g of original rat forebrain tissue. The regional distribution of NaCl-dependent [3H]NO 328 binding followed that of synaptosomal [3H]GABA uptake.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299358     DOI: 10.1111/j.1471-4159.1990.tb01919.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  26 in total

Review 1.  Role of astrocytes in the maintenance and modulation of glutamatergic and GABAergic neurotransmission.

Authors:  Arne Schousboe
Journal:  Neurochem Res       Date:  2003-02       Impact factor: 3.996

2.  Effects of γ-Aminobutyric acid transporter 1 inhibition by tiagabine on brain glutamate and γ-Aminobutyric acid metabolism in the anesthetized rat In vivo.

Authors:  Anant B Patel; Robin A de Graaf; Douglas L Rothman; Kevin L Behar
Journal:  J Neurosci Res       Date:  2015-02-06       Impact factor: 4.164

Review 3.  Delineation of the Role of Astroglial GABA Transporters in Seizure Control.

Authors:  Arne Schousboe; Karsten K Madsen
Journal:  Neurochem Res       Date:  2017-02-11       Impact factor: 3.996

4.  Ion binding and permeation at the GABA transporter GAT1.

Authors:  S Mager; N Kleinberger-Doron; G I Keshet; N Davidson; B I Kanner; H A Lester
Journal:  J Neurosci       Date:  1996-09-01       Impact factor: 6.167

Review 5.  Drug treatment of epilepsy in the 1990s. Achievements and new developments.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

6.  Comparative effects of the GABA uptake inhibitors, tiagabine and NNC-711, on extracellular GABA levels in the rat ventrolateral thalamus.

Authors:  D A Richards; N G Bowery
Journal:  Neurochem Res       Date:  1996-02       Impact factor: 3.996

Review 7.  The GABA synapse as a target for antiepileptic drugs: a historical overview focused on GABA transporters.

Authors:  Arne Schousboe; Karsten K Madsen; Melissa L Barker-Haliski; H Steve White
Journal:  Neurochem Res       Date:  2014-03-14       Impact factor: 3.996

Review 8.  Choice and use of newer anticonvulsant drugs in older patients.

Authors:  L J Willmore
Journal:  Drugs Aging       Date:  2000-12       Impact factor: 3.923

9.  Stereoselective central nervous system effects of the R- and S-isomers of the GABA uptake blocker N-(4, 4-di-(3-methylthien-2-yl)but-3-enyl) nipecotic acid in the rat.

Authors:  A Cleton; H J de Greef; P M Edelbroek; R A Voskuyl; M Danhof
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

10.  Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.

Authors:  John C Oakley; Alvin R Cho; Christine S Cheah; Todd Scheuer; William A Catterall
Journal:  J Pharmacol Exp Ther       Date:  2013-02-19       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.